GLP1R and neuroendocrine carcinoma: GLP‐1R is highly expressed on pancreatic β‐cells, and in case of certain endocrine and neuroendocrine cancers, including insulinoma, the density of such receptor is even higher, representing a valuable molecular target.[4, 5] Its natural ligand GLP‐1 is secreted by intestine in response to nutrients intake,[6] but is rapidly (<2 minutes) degraded by dipeptidyl peptidase‐IV (DPP‐IV), making the use of more stable agonists necessary for therapeutic purposes.[7, 8] Ex‐4 is a 39 amino acid peptide with a higher half‐life in plasma,[9] capable of binding GLP‐1R selectively with picomolar activity.